Priority review your cooked

Quote

Anonymous said:
Net sales in the Specialty Pharmaceuticals segment for the first quarter of fiscal 2014 were $309.5 million, an increase of 18.9%, compared with $260.2 million in the prior-year period. Operational growth was 19.1%. Net sales in Brands were $59.6 million, compared with $46.6 million last year, led by net sales from EXALGO(R) (hydromorphone HCl) Extended-Release Tablets, CII. Net sales in Generics and Active Pharmaceutical Ingredients (API) were $249.9 million, compared with $213.6 million last year, primarily driven by net sales from Methylphenidate HCl Extended-Release Tablets, USP CII (Methylphenidate ER) and the net benefit from pricing actions on certain specialty generics products.

Where are you getting $230 million?. Actavis generic approved but not available yet (or only recently)?

Can't explain 2013 results for first 2 quarters of 2014.
Click to expand...

Click on the link and read this paragrap-

"Exalgo® is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. For the 12 months ending February 28, 2014, Exalgo® had total U.S. sales of approximately $230 million, according to IMS Health data."

http://www.actavis.com/news/news/thomson-reuters/actavis-receives-final-approval-for-generic-versio
 
















































Top Bottom
Back
Quote